Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities

Biochemical Pharmacology

Volumn 53, Issue 3, 1997, Pages 287-298

  Nowak, Frédérique ^a   Jacquemin Sablon, Alain ^b   Pierre, Josiane ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

epithelial cells; MAP kinase; MEK; oncogene; signal transduction; tyrphostin

Indexed keywords

ALPHA CYANOTHIOCAFFEIC ACID AMIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; TYRPHOSTIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CATECHOLS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0031048034     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00688-0     Document Type: Article

References (44)

1. Guillick WJ, Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Brit Med Bull 47: 87-98, 1991.
2. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH, Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
3. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA and Di Fiore PP, Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831-838, 1989.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
5. Kraus MH, Popescu NC, Ambsbaugh SC and King CR, Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610, 1987.
6. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL and Marks P, Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
7. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR and Aaronson SA, erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 237: 178-182, 1987.
8. Di Marco E, Pierce JH, Knickley CL and Di Fiore PP, Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 10: 3247-3252, 1990.
9. HER2 causes transformation and tumorigenesis in NIH3T3 cells. Proc Natl Acad Sci USA 84: 7159-7163, 1987.
10. Schetcher AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI and Weinberg RA, The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984.
11. Bargmann CI, Hung M-C and Weinberg RA, Multiple independent activations of the neu ongogene by a point mutation altering the transmembrane domain of p185. Cell 45: 649-657, 1986.
12. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A and Greene MI, The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109-2123, 1994.
13. c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc Natl Acad Sci USA 89: 1330n1334, 1992.
14. Egan SE and Weinberg RA, The pathway to signal achievement. Nature 365: 781-783, 1993.
15. Davis RJ, The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993.
16. Anderson NG, Maller JL, Tonks NK and Sturgill TW, Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343: 651-653, 1990.
17. Burke Jr TR, Protein-tyrosine kinase inhibitors. Drugs Future 17: 119-131, 1992.
18. Levitzki A and Gazit A, Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
19. Ohmichi M, Pang L, Ribon V, Gazit A, Levitzki A and Saltiel AR, The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 32: 4650-4658, 1993.
20. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitzki A, Zilberstein A and Mundy GR, The antiproliferative effects of tyrosine kinase bors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 41: 4430-4435, 1991.
21. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A and Schlessinger J, Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF stimulated cell proliferation. J Biol Chem 264: 14503-14509, 1989.
22. Dvir A, Milner Y, Chomsky O, Gilon C, Gazit A and Levitzki A, The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J Cell Biol 113: 857-865, 1991.
23. Posner I, Gazit A, Gilon C and Levitzki A, Tyrphostins inhibit the epidermal growth factor receptor-mediated breakdown of phosphoinositides. FEBS Lett 257: 287-291, 1989.
24. Margolis B, Rhee SG, Felder S, Mervic M, Lyall R, Levitzki A, Ullrich A, Zilberstein A and Schlessinger J, EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signalling. Cell 57: 1101-1107, 1989.
25. Brunton GV, Carlin S and Workman P, Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine inhibitor. Anti-Cancer Drug Des 9: 311-329, 1994.
26. Agbotounou WK, Levitzki A, Jacquemin-Sablon A and Pierre J, Effects of tyrphostins on the activated c-src protein in NIH-3T3 cells. Mol Pharmacol 45: 922-931, 1994.
27. Faaland CA, Mermelstein FH, Hayash J and Laskin JD, Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity. Mol Cell Biol 11: 2697-2703, 1991.
28. Ramdas L, McMurray S and Budde RJA, The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability. Cancer Res 54: 867-869, 1994.
29. Agbotounou WK, Mousset S, Piperno S, Pierre M, Jacquemin-Sablon A and Pierre J, Activation of the mitogen activated protein kinase cascade by tyrphostin (RG 50864). Biochem Pharmacol 48: 505-515, 1994.
30. Yaish P, Gazit A, Gilon C and Levitzki A, Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242: 933-935, 1988.
31. Gardner AM, Lange-Carter CA, Vaillancourt RR and Johnson GL, Measuring activation of kinases in mitogen-activated protein kinase regulatory network. Methods Enzymol 238: 258-270, 1994.
32. Lavialle C, Modjtahedi N, Cassingena R and Brison O, High c-myc amplification level contributes to the tumorigenic phenotype of the human breast carcinoma cell line SW613-S [correction]. Oncogene 5: 245, 1990.
33. Lavialle C, Modjtahedi N, Cassingena R and Brison O, High c-myc amplification level contributes to the tumorigenic phenotype of the human breast carcinoma cell line SW613-S. Oncogene 3: 335-339, 1988.
34. Lavialle C, Modjtahedi N, Lamonerie T, Frebourg T, Landin RM, Fossar N, Lhomond G, Cassingena R and Brison O, The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers [review] Anticancer Res 9: 1265-1280, 1989.
35. Graham F and Van der Eb A, A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 73: 456-457, 1973.
36. Peraldi P, Scimeca JC, Filloux C and Van Obberghen E, Regulation of extracellular signal-regulated protein kinase-1 (ERK-1; pp44/ mitogen-activated protein kinase) by epidermal growth factor and nerve growth factor in PC12 cells: implication of ERK1 inhibitory activities. Endocrinology 132: 2578-2585, 1993.
37. c-erb-2 Signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758-3765, 1994.
38. Jallal B, Schlessinger J and Ullrich A, Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p 185HER2/neu-overexpressing human tumor cells. J Biol Chem 267: 4357-4363, 1992.
39. Kolch W, Heidecker G, Kochs G, Hummel H, Vahldl H, Mischak H, Finkenzeller G, Marmé D and Rapp UR, Protein kinase Cα activates Raf-1 by direct phosphorylation. Nature 349: 249-252, 1993.
40. Wolbring G, Hollenberg MD and Schnetkamp PPM, Inhibition of GTP-utilizing enzymes by tyrphostins. J Biol Chem 269: 22470-22472, 1994.
41. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M and Mumby M, The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the MAP kinase pathway and induces cell proliferation. Cell 75: 887-897, 1993.
42. Haystead TAJ, Weiel JE, Litchfield DW, Tsukitani Y, Fischer EH and Krebs EG, Okadaic acid mimics the action of insulin in stimulating protein kinase activity in isolated adipocytes. J Biol Chem 265: 16571-16580, 1990.
43. Zhang F, Strand A, Robbins D, Cobb MH and Goldsmith EJ, Atomic structure of the MAP kinase ERK2 at 2.3 resolution. Nature 367: 704-7111, 1994.
44. Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.